Industry
Biotechnology
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 27, 2024 | 9:36 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 11:46 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 8:35 pm
Portfolio Pulse from Benzinga Newsdesk
June 03, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Insights
May 31, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 3:12 pm
Portfolio Pulse from Benzinga Insights
May 27, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
May 27, 2024 | 12:05 pm
Portfolio Pulse from Avi Kapoor
May 24, 2024 | 5:57 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.